QUICK POLL
If imatinib, nilotinib, and dasatinib are all approved for front-line therapy of newly diagnosed chronic phase (CP) chronic myelogenous leukemia (CML), what would you recommend as front-line therapy for a 42-year-old man who presents with high-risk CML by both the Sokal and Hasford (Euro) scoring systems and who has no matched sibling donor?
Contact Imedex
For questions or problems concerning registering for a live event, registering for the e-Learning Center, obtaining CME certificates or Certificates of Attendance, to request an invitation letter, or for general inquiries, contact:
Imedex Customer Service
Tel: +1 (678) 242 0906; 1 (800) 233 0957
Fax: +1 (678) 242 0920
Email: meetings@imedex.com
For questions about support opportunities for live or e-learning activities or exhibiting at a live event, contact:
Imedex Business Development
Tel: +1 (770) 751 7332, 1 (800) 233 0957
Fax: +1 (770) 751 7334
Email: cme@imedex.com
For questions about careers at Imedex, contact:
Imedex Human Resources
Tel: +1 (770) 751 7332, 1 (800) 233 0957
Fax: +1 (770) 751 7334
Email: a.gant@imedex.com
Imedex, LLC
4325 Alexander Drive
Alpharetta, GA 30022, USA